Key points
- Completed enrolment of 250 participants in the HEALEY ALS Platform Trial in less than 5 months
- Secured long-term supply agreement with Elanco Animal Health
- Strengthened intellectual property protection for NUZ-001
- Raised approximately $20.8 million through equity raises
- Enhanced non-dilutive funding position
Full summary
Neurizon Therapeutics Ltd, a clinical-stage biotech company focused on neurodegenerative diseases, released its 2026 Annual Report. Key highlights include the completion of enrolment in the registrational Phase 2/3 HEALEY ALS Platform Trial, which enrolled 250 participants across 78 U.S. sites in less than five months, accelerating topline results to late Q2 CY2027. The company also secured a long-term supply agreement with Elanco Animal Health, providing access to GMP monepantel for continued clinical development and potential commercialization. Additionally, Neurizon strengthened its intellectual property position with the grant of an Australian patent extending protection through 2041. The company raised approximately $20.8 million through equity raises and strengthened its non-dilutive funding position by securing the Australian Government's R&D Tax Incentive and establishing an R&D financing facility.
Guidance
Topline results from the HEALEY ALS Platform Trial expected in late Q2 CY2027
Outlook
Neurizon Therapeutics Ltd is focused on disciplined execution of the HEALEY ALS Platform Trial, advancing regulatory engagement, strengthening the scientific evidence supporting NUZ-001, maintaining manufacturing readiness, and building organizational capability for future growth.